Fulcrum and Slalom work together to empower electrical, gas, and water utilities businesses to prioritize and realize the full potential of their AI investments

SAN FRANCISCO, Oct. 21, 2026 /PRNewswire/ -- Fulcrum, the Field Operations Management (FOM) platform for utilities and the service providers who serve them, today announced that it is working with Slalom, the fiercely human business and technology company. Together, the companies will help develop and deliver AI transformation solutions for field operations and business initiatives that require high-quality field data for analysis, process automation, and digital transformation.

"Utility leaders are being asked to invest in AI and to prove it pays off, and in field operations the payoff happens in the field," said Jim Grady, CEO of Fulcrum. "Slalom helps utilities decide where AI will make the biggest difference and measure what it delivers. Fulcrum replaces the many narrowly scoped field apps and all the pen and paper with a single platform for field operations, so AI gets the whole job to work on, not one slice of it."

AI investments can't improve utility business outcomes when operational field data remains fragmented across single-purpose mobile apps, spreadsheets, and paper forms. From routine inspections to storm restoration, unreliable frontline data undermines enterprise AI initiatives, while traditional office-based tools fail to solve the operational realities of field work.

Fulcrum replaces fragmented field tools with a single platform for running, recording, and closing out work. Slalom adds the strategy, tools, and services to help utilities scale AI transformation, process redesign, and adoption. Their AI Value Platform helps clients prioritize where to deploy AI, quantify value before investing, and measure realized outcomes. Together, Fulcrum and Slalom put AI to work in three areas.

AI for field operations. Fulcrum puts AI where fieldwork happens: Audio FastFill turns a crew member's spoken observations into structured form entries, hands-free. Fulcrum Insights improves office-based decision-making by answering plain-language questions against the complete field record. Finally, teams also use AI to build on Fulcrum: they describe the workflow they need and get back a working tool that inherits Fulcrum's security model, permissions, GIS and offline sync. Slalom helps organizations identify where these AI capabilities can make a practical difference and integrate them into field and office workflows. By enabling field teams to self-serve using a governed system, Fulcrum increases flexibility without encouraging shadow IT.

A data foundation for enterprise AI. Fulcrum validates every record at capture and ties it to a location, a time and a person, giving enterprise AI high-quality, defensible data it can put to work immediately. Teams can track where materials are installed for warranty work, how quickly inventory is used and where loss and breakage occur, then compare those patterns across projects. Slalom helps clients connect this trusted field data to enterprise priorities, so teams can build a path from better records to useful analytics and AI. As records accumulate and a reliable historical record develops, the same data supports periodic anomaly detection across projects. It also powers predictive models that guide asset maintenance and the vegetation work that reduces wildfire risk.

Quantifying the return on AI. Slalom's 2026 Global AI Insights Survey found that 91% of organizations plan to increase AI investment in 2026, yet only 39% track ROI. Slalom's AI Value Platform helps utilities assess and prioritize AI use cases based on business value and impact. As part of this collaboration, the platform can quantify benefits such as defensible records and decision-grade data, identify high-impact use cases, and track realized value against forecasts after go-live. It's proving the business case rather than simply promising it.

"Utilities are increasingly investing in AI as they respond to rising energy demand and prepare for more frequent extreme weather events and emergencies," said Tim Stafford, Global Lead for Energy & Natural Resources at Slalom. "Slalom brings the industry perspective and transformation experience to help utilities turn trusted field data into AI-powered operations, integrated with existing enterprise systems they rely on. Together with Fulcrum, we enable utilities to provide crews and leaders with defensible information to act with confidence and deliver critical work safely and reliably."

Utilities should visit fulcrumapp.com to contact their Fulcrum team to assess how Fulcrum and Slalom's joint capabilities can improve their business.

About Fulcrum

Fulcrum is the AI-native field operations management platform: the platform field organizations use to run, record, and close out their work. Almost 3,000 companies, across electric, gas, water and wastewater utilities and the service providers who serve them, use Fulcrum for asset management, vegetation management, linear construction, and disaster recovery and emergency response. Learn more at fulcrumapp.com.

About Slalom

Slalom is a fiercely human business and technology consulting company that leads with outcomes and champions leaders to dream big and build now. From strategy through delivery, our agile teams across 54 offices in 12 countries collaborate with clients to bring powerful customer experiences, innovative ways of working, and new products and services to life. We are trusted by leaders across the Global 1000, many successful enterprise and mid-market companies, and 500+ public sector organizations to improve operations, drive growth, and create value. At Slalom, we believe that together, we can move faster, dream bigger, and build better tomorrows for all.

SOURCE Fulcrum

Share this article

Moises and SoundCloud Partner to Bring AI-Supported Creation, Collaboration and Distribution Together for 150+ Million Artists

New integration enables artists to bring their SoundCloud tracks into Moises, utilize the first of its kind agentic creator suite, and publish directly back to SoundCloud to reach fans and unlock monetization opportunities.

SALT LAKE CITY, Oct. 21, 2026 /PRNewswire/ -- Moises, the ethically trained AI-powered creative suite used by 80 million musicians, and SoundCloud, the global music platform connecting artists and fans, today announced a new partnership that introduces a new generation of creative tools and distribution to artists worldwide, designed to make it easier for artists to create, collaborate, and share their music.

The integration connects SoundCloud's global artist and fan community with Moises' suite of AI-powered creative tools, enabling musicians to seamlessly bring their existing SoundCloud tracks into Moises to practice, produce, collaborate, and reimagine their work before publishing finished music directly back to SoundCloud.

Moises is redefining how musicians create, practice, and produce music through an AI-supported creative suite designed to enhance, rather than replace, human creativity. The platform brings professional-grade capabilities like stem separation, chord and lyric detection, AI-assisted mixing and mastering, and real-time collaboration into one accessible creative environment. With the introduction of Moi, its agentic production assistant, Moises is making sophisticated music production more intuitive, helping artists of all skill levels experiment with new sounds, refine their work, and bring their creative visions to life.

For nearly 20 years, SoundCloud has been a launchpad for music discovery and artist development, giving creators a place to experiment, share works-in-progress, connect with fans, and build careers on their own terms. This partnership builds on that foundation, connecting more of the creative process with the communities and audiences artists are building on SoundCloud.

Together, SoundCloud and Moises are helping lower the barriers between an artist's initial idea and its release, putting powerful creative technology within reach while keeping artists at the center of the process. By making it easier to move between creation and distribution, the partnership gives musicians more freedom to experiment, develop their sound, and bring their work to audiences around the world.

With the new integration, artists can:

- Import their own music: Connect their SoundCloud account and bring eligible tracks directly into Moises; via mobile or web.

- Practice and learn: Utilize Moises' industry-leading stem separation, chord detection, and lyric detection.

- Produce and collaborate: Open any track in Moises Studio (Moises' web-based audio studio) to mix it, master it, or reimagine the track with contextual stem generation. Artists can also invite producers and other artists to collaborate on their tracks in real-time.

- Just ask Moi: Moi is the first of its kind agentic production assistant designed specifically for audio workstations. Let Moi set up sessions, mix and master to your requirements, and teach musicians of all levels how to expand their creativity and achieve their sound.

- Release and monetize: Publish finished tracks directly back to SoundCloud, where eligible artists can reach listeners and monetize qualifying music.

"The goal continues to be the democratization of professional-grade tools for musicians," said Geraldo Ramos, founder and CEO of Moises. "SoundCloud has always led the way in supporting independent musicians and we couldn't be more proud to bring the first-ever agentic creative suite to their artists."

"SoundCloud has always been a place where artists experiment, push boundaries, and turn creative ideas into something bigger," said Eliah, CEO of SoundCloud. "Our partnership with Moises builds on that foundation by giving artists powerful new ways to develop their music, collaborate, and bring their work directly back to the communities they're building on SoundCloud. We believe the future of AI in music should be artist-first and human-first, with technology expanding creative possibilities while keeping artists in control. This integration is another step toward making that future a reality."

Advancing an artist-first approach to AI

The partnership reflects a shared belief that AI should serve as a tool for human creativity, helping musicians explore new possibilities while preserving their creative agency and control.

SoundCloud's approach to AI is grounded in the principles of consent, attribution, transparency, and creator control, supporting responsible innovation that expands opportunities for artists while protecting their rights and creative work. SoundCloud does not use artists' music to train generative AI models without their explicit consent.

Moises shares this commitment to responsible AI development. Its models are trained exclusively on licensed and authorized music, not on content that users upload or create within the platform. Rather than generating complete songs, Moises' tools are designed to support musicians as they practice, produce, and build upon their own creative ideas.

Together, the companies are demonstrating how AI-powered creative tools can complement human artistry while connecting musicians with the distribution, discovery, and monetization opportunities needed to grow their careers.

Exclusive benefits for SoundCloud and Moises subscribers

To make it easier for artists to explore both platforms, Moises Pro subscribers will receive a 2-month trial to SoundCloud Artist Pro, while SoundCloud Artist Pro members will similarly receive 2 month trials to Moises Pro.

About SoundCloud

SoundCloud empowers artists, tastemakers and fans to connect and share through music. Founded in 2007, SoundCloud is a creator-first platform helping artists build and grow their careers by providing them with the most advanced tools, services, and resources. With 500+ million tracks from 40+ million artists across 193 countries, SoundCloud is where emerging artists find their sound, hidden gems are discovered, and music culture is shaped in real time.

About Moises

Moises is the creative suite used by 80 million musicians worldwide, giving everyone from hobbyists to world-class artists studio-level tools to practice, perform, create, and collaborate across mobile, desktop, and web. Powered by more than 50 proprietary AI models, the platform processes nearly six years' worth of audio every day. Built by a global team with experience at Spotify, Pandora, and TikTok, Moises was named Apple's 2024 iPad App of the Year and is available worldwide in 33 languages.

SOURCE Moises

Share this article

AWS is investing in 3M's Expanded Beam Optical technology for its data center infrastructure

SAINT PAUL, Minn., Oct. 21, 2026 /PRNewswire/ -- 3M (NYSE: MMM) and Amazon Web Services (AWS) today announced an expanded strategic collaboration. AWS plans to deploy and scale 3M's Expanded Beam Optical (EBO) platform for its data center infrastructure. Together, the two leading American companies will advance co-innovation and investment in optical connectivity and the critical infrastructure needed for next-generation super intelligence (SI), also known as artificial intelligence (AI).

"AWS's adoption of 3M's EBO platform demonstrates the potential of our optical connectivity technology to meet the performance demands of next-generation data center infrastructure," said Wendy Bauer, Group President of 3M's Transportation and Electronics Business Group. "By combining AWS's infrastructure expertise and scale with 3M's innovation and materials science capabilities, we can accelerate EBO deployment, advance our transformation and strengthen U.S. innovation and investment."

"Our work with 3M reinforces our commitment to supporting good jobs here in the U.S.," said Jens Gruenkemeir, Vice President of Supply Chain & Procurement at Amazon. "Beyond powering the services people use every day, from online banking and hospital data records to streaming entertainment and retail purchases, our data center investments are unlocking economic opportunities in the communities where we invest and across the supply chain, including the hundreds of jobs being supported by 3M as a result of its collaboration with Amazon."

The collaboration and related investments are expected to strengthen the U.S. economy by supporting more than 500 jobs directly and indirectly, including the creation of more than 100 new roles through 2027 across Minnesota, Texas and Wisconsin. These planned roles will support customer co-innovation, technology advancement and supply chain development across 3M's optical networking portfolio and help accelerate industrywide adoption through collaboration with partners.

3M expects to contribute nearly $0.5 billion to the U.S. economy through its optical connectivity business. This investment will accelerate innovation in optical networking and fiber termination, enable commercialization at scale and drive adoption across the data center industry.

The collaboration builds on 3M's announcement earlier this year that it will double production capacity at its Menomonie, Wisconsin, manufacturing facility, and is expected to support U.S. manufacturing partners involved in equipment and production scale-up throughout the supply chain.

Forward-Looking Statements

Certain statements in this release are considered "forward-looking statements" under the federal securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, and are intended to enjoy the protection of those laws. Forward-looking statements may appear throughout this release and are typically identified by the words "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "evaluate," "expect," "forecast," "future," "goal," "guidance," "impact," "initial," "intend," "likely," "may," "outlook," "plan," "possible," "potential," "predict," "probable," "project," "seek," "should," "strategy," "target," "will," "would," and other words that are similar to, or have the opposite meanings of, those words. Forward-looking statements speak only as of the date they are made, 3M assumes no duty to update those statements, and readers are cautioned not to place undue reliance on any of those statements. Forward-looking statements are based on certain assumptions and expectations of future events and trends that are subject to risks and uncertainties, including those described in Part I, Item 1A, "Risk Factors" of 3M's Form 10-K for the year ended December 31, 2025.

About 3M

3M (NYSE: MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multidisciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footprint and operational excellence. Discover how 3M is shaping the future at 3M.com/news.

Contacts

3M Investor Contact:

Diane Farrow, 612-202-2449

3M Media Contact:

[email protected] 

SOURCE 3M Company

Share this article

Thirty new grants will enable park partners and parks to implement new approaches to natural resource management, public safety, interpretation, and more

WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- The National Park Foundation (NPF) has awarded $12 million in grants to support a second cohort of 30 new, innovative projects across the National Park System. This investment will benefit more than 40 national parks and enable collaboration between parks, park partners, and others to test new ideas and scalable technologies that will strengthen parks, expand what is possible, and ensure these extraordinary places endure for generations.

This second cohort builds on the inaugural launch of NPF's innovation grants earlier this year, bringing NPF's total investment in innovation in 2026 to nearly $25 million and expanding into new focus areas like interpretation and natural resource management. Grantees will experiment with ideas that can improve how parks manage natural, cultural, and historic resources; strengthen public safety; make visitor information more accessible; and deepen partnerships.

Like the first round of grants, these projects are designed to solve site-specific challenges while producing models and tools other parks can use. Parks and partners will participate in learning groups, working with NPF and the National Park Service (NPS) to replicate what works, address barriers to scale, and share relevant lessons with other parks. Every project was developed by parks and their partners, reflecting NPF's commitment to empower those closest to the work.

A few highlights include:

- Washington's National Park Fund will partner with NPS' North Coast and Cascades Network and scientists at Mount Rainier, North Cascades, and Olympic National Parks to develop an AI-enabled hazard forecasting system that turns weather, hydrologic, snowpack, vegetation, and lightning-strike data into actionable information for park management to make earlier and more precise decisions about closures, staffing, emergency response, infrastructure protection, and visitor safety.

- Lincoln Presidential Foundation will connect six NPS sites in Illinois, Indiana, and Kentucky that tell the story of Abraham Lincoln's life and legacy, supporting a shared network of virtual tours, 3D documentation, and multilingual, accessible self-guided experiences that expand access onsite and online, support newer park units with limited visitor facilities, and offer a model for other parks seeking to link sites in different places into one story.

- Rocky Mountain Conservancy will develop protocols for and conduct thermal infrared aerial surveys at Rocky Mountain National Park to improve monitoring of moose populations, inform adaptive wildlife management and wetland restoration, and establish methods other parks can adapt for wildlife population monitoring.

- Chalon Indian Council of Bakersfield will strengthen tribal co-stewardship at Pinnacles National Park by training Chalon Indian Nation tribal members in low-impact archeological sensing technologies, cultural monitoring, and approaches that integrate Indigenous values into cultural resource management.

- Independence Historical Trust will launch a drone program at Independence National Historical Park to support the park during large events and emergencies and enable staff to more easily inspect roofs and hard-to-reach features of the park's aging historic buildings.

View the full list of grants included in the second cohort here.

"National parks have always represented a bold idea, and their future depends on continued innovation," said NPF Chief Program Officer Mike Reynolds. "The National Park Foundation was inspired by the overwhelming interest from parks and park partners, and we are proud to double down on our support for their new ideas that can make their parks safer, more resilient, and more enjoyable and meaningful for the millions of people who experience them each year."

These grants are made possible with the support of NPF's donors and partners, including Lilly Endowment Inc., Peter and Betsy Chung, Robert and Kitty Brunswick, Cody J Smith, The Ball Foundation, and Arconic Foundation.

The response from parks and park partners has been overwhelmingly positive, with more than 200 unique proposals received in 2026. NPF plans to open a call for 2027 projects in the coming months.

ABOUT THE NATIONAL PARK FOUNDATION

The National Park Foundation is the nation's most trusted way for people to support America's national parks. We work with the National Park Service and partners across the country to fund priority projects that keep parks strong, relevant, and accessible. This work helps ensure parks continue to inspire pride across the country and offer experiences that create meaningful connection. In 2025, NPF funded $100 million in on-the-ground priority projects nationwide, made possible through the generosity of donors, to advance critical work, including infrastructure, restoration, education, and access, ensuring parks continue to endure for generations to come. Learn more at nationalparks.org and follow NPF on Instagram, Facebook, X, LinkedIn, and TikTok.

SOURCE National Park Foundation

Share this article

New partnership will support student athletics, outdoor spaces, and families across Williamson County, Tennessee

FRANKLIN, Tenn., Oct. 21, 2026 /PRNewswire/ -- TruGreen, America's No. 1 lawn care company, today announced a new partnership with Williamson County School District, becoming an Official Partner of the Williamson County School District & Athletics. The partnership brings together two organizations with strong ties to the local community and creates new opportunities to support students, athletes, and families across Williamson County.

TruGreen is a Tennessee-based company with a support center located in Williamson County; the partnership provides an opportunity for the company and its local team to deepen its involvement in a community where many TruGreen employees live and work.

"Williamson County is an important community for TruGreen, not only because we operate here, but because many of our employees and their families live, work, and spend time here," said Kurt Kane, President & Chief Executive Officer at TruGreen. "We're proud to partner with Williamson County Schools and bring our expertise to the outdoor spaces that play such an important role in bringing students, athletes, and families together."

As part of the partnership, TruGreen's local team will work with Williamson County School District & Athletics to identify opportunities to support the district's grounds care needs through tailored commercial services, including fertilization, weed control, aeration, tree & shrub care, mosquito and tick treatment solutions. TruGreen will also serve as a resource to the coaches and field crews, bringing local expertise and customized solutions to help address the unique lawn care needs of the sports fields around the county.

TruGreen will also serve as an official sponsor of the 2027 WILLCO Awards in Spring 2027, an annual celebration recognizing local athletes, coaches, and their families.

Throughout the partnership, TruGreen will have a presence at various Williamson County Schools athletic events, creating opportunities to engage with students, families, and fans through interactive game-day experiences and activities. The company will also extend a special friends-and-family offer on residential lawn care services to the Williamson County Schools community. Additionally, TruGreen flags and banners will be displayed at home field stands and athletic facilities across the county reflecting the company's commitment to helping people enjoy the outdoor spaces where they live, work and play.

"We're grateful to welcome TruGreen as a partner and appreciate their investment in Williamson County Schools and our community," said Patrick Whitlock, Williamson County Athletics Director, at Williamson County School District. "This partnership gives our schools and athletic teams access to TruGreen's local expertise and commercial lawn care solutions while creating new opportunities to engage and celebrate our students, athletes and families throughout the year."

This partnership builds on TruGreen's broader commitment to supporting the communities where its employees and customers live and work while helping create outdoor spaces people can enjoy.

To learn more about the partnership & request services, visit our website here.

About TruGreen

Founded in 1973, TruGreen is the nation's leading lawn care provider, providing lawn, tree and shrub, and pest services focused on exceeding its customers' needs. The company operates more than 290 locations across the United States and Canada, with more than 14,000 employees. TruGreen is the partner with the local, tailored solutions and science-driven expertise needed to help each outdoor living space look and feel its very best. For more than 50 years, TruGreen has stayed committed to making its customers' outdoor living space a place they can be proud of. For more information about TruGreen, visit TruGreen.com and follow them on Facebook, Instagram, and X.

SOURCE TruGreen

Share this article

The Article Covers Cabin Size, Sleeping Arrangements, Amenities, and Location Factors That Can Shape a Family or Group Stay

BROKEN BOW, Okla., Oct. 21, 2026 /PRNewswire/ -- How do you choose the right Broken Bow cabin for your group? HelloNation published an article with the answer, featuring insights from Janine Carter of Beavers Bend Adventures Inc. in Broken Bow, Oklahoma.

The article explains that choosing a Broken Bow cabin begins with understanding how the group plans to use the property. Total square footage may be less important than bedroom arrangements, bathrooms, gathering spaces, and location. Cabin Rental Expert Janine Carter is featured as the source of insights on these practical considerations.

According to the article, travelers should first consider who is going and how each person prefers to sleep. Couples may value private bedrooms, while children may be comfortable in bunk rooms. Teenagers may benefit from a separate sleeping area or game room where they can spend time together.

The article notes that advertised guest capacity does not always tell the full story about cabin size. A property that sleeps 12 could depend on bunk beds, sleeper sofas, or shared bedrooms. Reviewing the actual bed configuration helps families determine whether the sleeping arrangements fit the ages and relationships within their group.

Bathrooms are another practical factor the article discusses. A cabin with many beds but limited bathrooms can create crowded mornings and evenings. Families with younger children may also find it helpful to have bathrooms located close to sleeping areas.

The HelloNation article also examines shared indoor spaces for a family trip. An open living area can accommodate meals and conversation, while a separate game room can give children and teenagers another place to gather. This extra indoor space may become especially useful during rainy weather or longer visits.

Kitchen features should also match the group's plans. The article recommends considering refrigerator capacity, counter space, dining seating, and available cookware when guests expect to prepare meals. For larger groups, a functional kitchen and dining area may be more useful than features the group will rarely use.

Outdoor areas are another part of evaluating a family-friendly cabin. Covered decks can provide gathering space when weather changes, while fire pits, hot tubs, seating, and play areas may suit different ages and interests. The article advises comparing cabin amenities with activities the group can realistically enjoy.

For families with children, the article explains that practical layout details can make a difference. Bunk rooms, shared spaces, and recreation areas may help, but parents should also consider stairs, deck design, and distances between bedrooms. Cabin Rental Expert Janine Carter's insights help frame these details around how families actually use a property.

Location can influence the experience as much as the cabin itself. The article notes that some groups prefer quieter surroundings, while others value convenient access to restaurants and attractions. Frequent outings can make driving time, road access, parking, steep roads, and seasonal conditions important considerations.

The article concludes that selecting a Broken Bow cabin involves balancing privacy, shared space, location, and practical amenities. Rather than choosing a property based on its longest list of features, travelers can focus on the features that support their group's plans.

How to Choose the Right Broken Bow Cabin for Your Group features insights from Janine Carter, Broken Bow, Oklahoma, Cabin Rental Expert, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

DELRAY BEACH, Fla., Oct. 21, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Regenerative Medicine Market is projected to reach USD 62.69 billion by 2031 from USD 23.90 billion in 2026, at a CAGR of 21.3% during the forecast period.

Browse 297 market data Tables and 57 Figures spread through 295 Pages and in-depth TOC on "Regenerative Medicine Market - Global Forecast to 2031"

Regenerative Medicine Market Size & Forecast:

- Market Size Available for Years: 2026–2031

- 2026 Market Size: USD 23.90 billion

- 2031 Projected Market Size: USD 62.69 billion

- CAGR (2026–2031): 21.3%

Regenerative Medicine Market Trends & Insights:

- North America accounted for the largest market share of ~52.3% in 2025.

- By product, cell therapy segment accounted for the largest market share of ~47.6% in 2025.

- By therapeutic area, oncology is the fastest-growing segment, registering a CAGR of 22.3% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579

The growth of the regenerative medicine market is characterized by increasing collaborations and partnerships among major market players and the emerging applications in new therapeutic areas. Rising focus on personalized medicine and increasing regulatory approvals in regenerative medicine are also predicted to drive the market.

The cell therapy segment accounted for the largest share of the regenerative medicine market.

Based on product, the regenerative medicine market is segmented into cell therapy, gene therapy, and tissue engineering. Cell therapy includes stem cell therapy, cell transplantations, stem cell therapy products such as autologous and allogeneic therapies, and cell-based immunotherapy products. Expanding adoption of CAR-T and other cellular therapies, increasing stem cell applications, growing treatment-center capabilities, and continued regulatory approvals are supporting the segment's growth. Gene therapy and tissue engineering are also gaining momentum as developers broaden disease targets and advance regenerative approaches for tissue repair and functional restoration.

The musculoskeletal disorder segment accounts for the largest share of the regenerative medicine market.

By therapeutic area, the regenerative medicines market covers oncology, musculoskeletal disorders, dermatology & wound care, cardiovascular diseases, ophthalmology, neurology, and other applications. Musculoskeletal applications remain important due to the high burden of orthopedic disorders, cartilage and bone injuries, and growing research into regenerative approaches for tissue repair. At the same time, cell-based immunotherapies continue to expand in oncology, while gene therapies are broadening treatment options in neurological and ophthalmic diseases. Tissue-engineered products are gaining use in wound care and reconstructive applications.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=65442579

North America dominated the global regenerative medicine market in 2025.

North America accounts for the largest share of the global regenerative medicine market, closely followed by Europe and Asia Pacific. This can be attributed to the growth of stem cell research, healthcare sector expansion, and the increase in the adoption of stem cell therapy and cell immunotherapies for cancer and other chronic disease treatment.

Key Players

Leading players in the Regenerative Medicine companies include Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Vericel Corporation (US), MIMEDX Group, Inc. (US), Organogenesis Inc. (US), Medtronic plc (Ireland), and Bristol-Myers Squibb Company (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65442579

Regenerative Medicine Market- Investment & funding +Merger & Acquisition

Investment Funding Context

The regenerative medicine market continues to attract substantial venture capital and government funding across cell therapy, gene therapy, and tissue engineering, with investment increasingly directed toward clinical-stage assets, next-generation manufacturing platforms, and technologies capable of improving scalability and patient access. In January 2025, Aspect Biosystems raised USD 115 million in Series B financing to advance its bioprinted tissue therapeutics platform, which integrates therapeutic cells, biomaterials, AI-enabled bioprinting, and tissue engineering technologies. In April 2025, Neurona Therapeutics secured USD 102 million to support the Phase III development of NRTX-1001, a regenerative cell therapy for epilepsy, and advance its broader cell therapy pipeline. Neurona Therapeutics Public-sector funding also remains significant; the California Institute for Regenerative Medicine approved a USD 662 million research budget for FY2026–27, its largest annual investment to date, to accelerate stem cell and gene therapy research and clinical development. Additionally, ARPA-H committed up to USD 87 million under its BioStabilization Systems program to develop room-temperature preservation technologies for cell-based biologics, highlighting investment in infrastructure intended to reduce cold-chain dependence and improve therapy accessibility. These developments indicate sustained funding across therapeutic development, manufacturing, preservation, and commercialization capabilities.

Revenue Shift Context

The regenerative medicines market is gradually transitioning from a predominantly research- and clinical-stage industry toward a broader commercial revenue base, supported by increasing uptake of approved cell therapies, gene therapies, and tissue-engineered products. In 2025, CARVYKTI generated approximately USD 1.9 billion in worldwide sales, with Johnson & Johnson attributing growth partly to continued share gains and manufacturing capacity expansion. SEC Bristol Myers Squibb reported USD 1.36 billion in Breyanzi revenue and USD 427 million from Abecma, illustrating the expanding commercial contribution of CAR-T therapies. Gilead's cell therapy revenue declined 7% to USD 1.8 billion in 2025, including USD 1.5 billion from Yescarta and USD 344 million from Tecartus, reflecting increasing competition within established CAR-T indications. Overall, revenue opportunities are increasingly shifting toward commercially validated therapies, expanded indications, manufacturing capacity, and broader penetration of regenerative products across oncology, musculoskeletal disorders, and wound care.

Mergers and Acquisitions

Mergers and acquisitions in the regenerative medicine market during January 2025–July 2026 have increasingly focused on strengthening cell therapy, gene therapy, and regenerative medicine pipelines, while gaining access to differentiated delivery platforms, late-stage therapeutic assets, and commercial manufacturing capabilities. Large pharmaceutical and healthcare companies are using acquisitions to expand into CAR-T and in vivo cell therapies, ophthalmic regenerative therapies, neurological cell therapies, and commercial gene therapy portfolios. These transactions also reflect growing interest in technologies that can simplify manufacturing, improve scalability, and broaden patient access to advanced therapies.

REGENERATIVE MEDICINE MARKET: MERGERS AND ACQUISITIONS, JANUARY 2025–JULY 2026

Company Revenue Share Details

The total market share of the top five players in the regenerative medicine market is estimated at around 40–45%, indicating a moderately concentrated competitive landscape. Leading participants include Sarepta Therapeutics, Gilead Sciences, Bristol Myers Squibb, Novartis, and Biogen, which collectively hold a significant share of the market through their established portfolios across gene therapy, cell-based immunotherapy, and other regenerative medicine products.

These companies compete on the basis of commercialized product portfolios, clinical pipeline strength, therapeutic efficacy, regulatory approvals, manufacturing capabilities, geographic reach, and strategic collaborations. The market also includes a broad base of mid-sized and emerging regenerative medicine companies focused on stem cell therapy, tissue engineering, wound care, musculoskeletal regeneration, and next-generation cell and gene therapies. Competition is expected to intensify as companies expand indications, scale manufacturing capacity, pursue acquisitions and licensing agreements, and develop advanced autologous, allogeneic, and gene-modified therapies across oncology, musculoskeletal disorders, neurology, ophthalmology, and other therapeutic areas.

Browse Adjacent Market: Biotechnology Market Research Reports &Consulting

See More Latest Biotechnology Reports:

CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031

Stem Cell Therapy Market by Cell Source (Adipose Tissue, Bone Marrow, Placenta, Umbilical Cord, iPSC), Type (Autologus Stem Cell), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological), End User - Global Forecast to 2035

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth.

DelveInsight's analysis predicts significant growth in the cystic fibrosis market from 2026 to 2036, driven by the launch of emerging therapies such as Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), and others, and increased global healthcare spending. The introduction of new treatments and rising healthcare investments will expand market opportunities and improve patient outcomes.

LAS VEGAS, Oct. 21, 2026 /PRNewswire/ -- Recently published Cystic Fibrosis Market Insights report includes a comprehensive understanding of current treatment practices, cystic fibrosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Cystic Fibrosis Market Summary

- The total cystic fibrosis treatment market size is expected to grow positively by 2036 in the leading markets.

- The United States accounted for the largest cystic fibrosis treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

- There were around 35K diagnosed prevalent cases of cystic fibrosis in the US in 2025, with this number projected to rise over the forecast period from 2026 to 2036.

- Leading cystic fibrosis companies, such as Spexis, Laurent Pharmaceuticals, Arcturus Therapeutics, 4D Molecular Therapeutics, Krystal Biotech, SpliSense, ReCode Therapeutics, Vertex Pharmaceuticals, and others, are developing new cystic fibrosis treatment drugs that can be available in the cystic fibrosis market in the coming years.

- The promising cystic fibrosis therapies in clinical trials include Lonodelestat, LAU-7b, ARCT-032, 4D-710, KB407, SPL84, SPL23, RCT2100, Ivacaftor, and others.

Discover the future of the cystic fibrosis therapeutics market @ https://www.delveinsight.com/report-store/cystic-fibrosis-market

Key Factors Driving the Growth of the Cystic Fibrosis Market

- Rising Prevalence of Cystic Fibrosis: The growing prevalence and continued identification of cystic fibrosis cases are expanding the overall patient pool requiring long-term treatment and disease management. Improved disease recognition and screening are also contributing to higher case detection across various regions.

- Expanding Adoption of CFTR Modulators: Increasing use of CFTR modulator therapies is a major market driver, particularly as more patients become eligible for genotype-specific treatments. Wider adoption of highly effective modulator combinations is improving clinical outcomes and supporting sustained treatment demand.

- Increasing Focus on Personalized Medicine: Greater understanding of CFTR mutations is enabling treatment strategies tailored to individual genetic profiles. The growing emphasis on precision medicine is supporting the development and adoption of mutation-specific and personalized therapeutic approaches.

- Development of Next-Generation Therapies: Pharmaceutical companies are pursuing novel therapies, including Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), SPL84 and SPL23 (SpliSense), RCT2100 (ReCode Therapeutics), Ivacaftor (Vertex Pharmaceuticals), and others. These innovations could expand treatment options for patients who remain underserved by existing therapies.

Shikha Bhardwaj, Associate Consultant of Forecasting & Analytics at DelveInsight, said, "ALYFTREK demonstrates strong clinical and commercial value, with the potential to deliver improved patient outcomes and convenient once-daily dosing, supported by rapid NHS access and reimbursement agreements that are enhancing adoption."

Cystic Fibrosis Market Analysis

- The cystic fibrosis treatment landscape is undergoing significant transformation, largely driven by the widespread adoption of CFTR modulators, which are now accessible to the majority of eligible patients. This shift is positioning cystic fibrosis increasingly as a chronic, manageable condition.

- However, substantial unmet needs remain among patients who are not eligible for CFTR modulators, while persistent disparities in global treatment access continue to influence innovation and market expansion.

- The cystic fibrosis market is largely dominated by CFTR modulators, with Vertex Pharmaceuticals maintaining a strong leadership position through its portfolio of ALYFTREK, TRIKAFTA, SYMDEKO, and ORKAMBI, which collectively contribute a significant share of global market revenues.

- Market expansion is being supported by broader access and label extensions for CFTR modulators, including their use in younger age groups and patients with a wider range of CFTR mutations.

- The market is anticipated to experience steady growth, supported by sustained uptake of established therapies and the emergence of novel treatments offering improved efficacy, broader patient coverage, and potentially disease-modifying effects.

- The evolving pipeline, which includes candidates such as Lonodelestat, LAU-7b, and ARCT-032, among others, highlights ongoing efforts to address residual unmet needs, expand treatment options, and further improve outcomes for patients with cystic fibrosis.

Cystic Fibrosis Competitive Landscape

Some of the cystic fibrosis drugs under development include Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), SPL84 and SPL23 (SpliSense), RCT2100 (ReCode Therapeutics), Ivacaftor (Vertex Pharmaceuticals), and others.

Spexis' Lonodelestat is an investigational inhaled therapy designed to inhibit neutrophil elastase, an enzyme associated with pulmonary inflammation and tissue damage in patients with cystic fibrosis. By blocking neutrophil elastase activity, Lonodelestat is intended to reduce lung inflammation and potentially preserve or improve pulmonary function. The therapy is currently being evaluated in Phase II clinical trials to assess its safety and efficacy in cystic fibrosis. Findings from these studies will help determine its potential for further development, regulatory approval, and clinical use.

Laurent Pharmaceuticals' LAU-7b (fenretinide) is a novel oral formulation of fenretinide, an atypical retinoid that modulates specific cell membrane lipids involved in viral replication and immune-inflammatory pathways. As the company's lead drug candidate, LAU-7b is a patent-protected oral formulation designed to support a convenient once-daily, low-dose treatment regimen. The candidate has completed Phase II clinical development for cystic fibrosis.

Arcturus Therapeutics' ARCT-032 is an investigational inhaled mRNA therapy delivered using LUNAR, a lipid-mediated delivery platform that encapsulates mRNA within lipid nanoparticles. In February 2024, the European Commission granted Orphan Medicinal Product Designation to ARCT-032 for the treatment of cystic fibrosis following a positive opinion from the European Medicines Agency. The candidate had previously received Rare Pediatric Disease Designation from the FDA in October 2023 and Orphan Drug Designation in November 2023. In October 2025, the company reported interim results from its ongoing Phase II clinical trial evaluating ARCT-032 in patients with cystic fibrosis.

4D Molecular Therapeutics' 4D-710 is an investigational genetic medicine candidate that utilizes the A101 vector to target the underlying cause of cystic fibrosis lung disease. The candidate is being evaluated in a Phase 1/2 clinical study in patients with cystic fibrosis who are ineligible for CFTR modulator therapy or have discontinued treatment because of adverse effects. 4D-710 is designed for single-dose aerosol administration to deliver a corrective CFTRΔR transgene throughout the airways and alveoli. Its mutation-agnostic approach is intended to provide a disease-modifying effect regardless of the patient's specific CFTR mutation.

The anticipated launch of these emerging therapies are poised to transform the cystic fibrosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the cystic fibrosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the cystic fibrosis treatment pipeline @ Cystic Fibrosis Drug Pipeline

Cystic Fibrosis Epidemiology Segmentation

The cystic fibrosis epidemiology section provides insights into the historical and current cystic fibrosis patient pool and forecasted trends for the leading markets. Recent trends in cystic fibrosis indicate that Staphylococcus aureus and Pseudomonas aeruginosa remain the most prevalent pathogens, driving a large share of infections.

Mérieux NutriSciences Completes Acquisition of Certified Group, Becoming North America's Leading Food Testing Provider

CHICAGO, Oct. 21, 2026 /PRNewswire/ -- Mérieux NutriSciences, a global leader in food safety, quality, and sustainability, today announced the successful completion of its acquisition of Certified Group.

First announced in August 2026, this strategic transaction unites two complementary leaders in the Testing, Inspection, and Certification (TIC) sector. With approximately $300 million in revenue, Certified Group brings 31 laboratories and over 1,600 talented employees into Mérieux NutriSciences' global network. The integration also adds a robust roster of more than 170 independent regulatory consultants across the United States and Canada.

With this expanded coast-to-coast footprint, Mérieux NutriSciences is positioned to provide customers with broader service offerings and enhanced regulatory support. The integration deepens the company's capabilities in key Food & Beverage segments, most notably in animal protein through its Food Safety Net Services (FSNS) network, where Certified Group has built a strong reputation as a bellwether for safety and quality, alongside leading positions in dairy, packaged foods, nuts, and spices.

Customers will also benefit from high-value expertise in cosmetics, OTC products, and dietary supplements through the Certified Laboratories vertical, and reduced-harm nicotine product testing via Labstat International. These core verticals are further bolstered by specialized expert services, including contract research (Lab Plus), regulatory consulting (EAS Consulting Group), and comprehensive certification and audit programs (FSNS Certification and Audit).

"We are thrilled to officially welcome the talented teams from Certified Group to the Mérieux NutriSciences global network," said Nicolas Cartier, CEO of Mérieux NutriSciences. "By combining our respective strengths, we are vastly expanding the depth and breadth of our capabilities. This milestone allows us to be closer to our customers, meeting their localized, time-sensitive needs with unmatched speed and reliability, while furthering our shared purpose: Better Food. Better Health. Better World."

"Our priority is to ensure a seamless transition for all customers while delivering immediate, enhanced value," added Sébastien Moulard, President North America at Mérieux NutriSciences. "Through this nationwide analytical network, customers now have access to a truly comprehensive portfolio of routine testing, specialized analysis, expert regulatory support, and more. We are excited to leverage the best of both worlds to drive innovation and provide practical solutions right where production happens."

"Certified Group has built a differentiated platform with a strong reputation for quality, scientific excellence and exceptional customer service," said Deborah Kerr, Managing Director, Warburg Pincus & Executive Chair, Certified Group. "We are proud to have supported Certified Group's evolution and look forward to seeing the company continue to thrive as part of Mérieux NutriSciences."

The financing of the acquisition brings new minority shareholders Peugeot Invest and Continental Grain Company (Conti) alongside Mérieux NutriSciences' long standing shareholders: Institut Mérieux, Sofina, and Dassault Group. This collective support underscores strong market confidence in the company's strategic vision. Ultimately, the successful integration of Certified Group solidifies Mérieux NutriSciences as the leading provider in North America and a top player in the global food TIC market, further cementing its role as the trusted partner for customers navigating a rapidly evolving landscape.

About Mérieux NutriSciences:

At Mérieux NutriSciences, we leverage 60 years of scientific and entrepreneurial expertise to answer food industry needs. Today's global challenges transform the way food is produced, marketed and consumed, which is why we know our clients need more than reliable analytical results; they need practical and innovative solutions that will contribute to make food systems safer, healthier and more sustainable. Present worldwide, we are more than 160 accredited laboratories and a team of over 11,600 committed employees. We strongly believe that together, we can create solutions to offer our planet: BETTER FOOD. BETTER HEALTH. BETTER WORLD. na.mxns.com

MERIEUX NUTRISCIENCES

Stephen Nichols (North America)

[email protected] 

Marion Bertrand (Global)

[email protected] 

Ashton van den Bergh (Global)

[email protected]

SOURCE Mérieux NutriSciences

Share this article

Financial institutions, fintechs honored for innovation, impact, and empowering financial freedom

MONETT, Mo., Oct. 21, 2026 /PRNewswire/ -- Jack Henry® (Nasdaq: JKHY) is proud to announce the winners of the 2026 Cobalt Awards – six financial institutions and fintechs that are using innovation, integration, and technology to create meaningful impact for the communities they serve.

This year's honorees, Local Bank, Numerica Credit Union, FirstBank, Kitsap Credit Union, Array, and Moov, were selected for their outstanding achievements in using technology to drive operational excellence, improve financial outcomes, and empower people to move forward with confidence.

The winners were revealed this week during the 2026 Jack Henry® Connect annual client conference.

"The Cobalt Awards celebrate organizations that are finding new ways to strengthen their communities through innovation," said Jack Henry President and CEO Greg Adelson. "We're honored to recognize this year's winners for delivering solutions that improve financial access, enhance efficiency, and help people achieve better financial outcomes."

2026 Cobalt Award Winners

The Barrier Breakers

Recognizes financial institutions for tearing down barriers to financial health

- Local Bank – Expanded financial access and literacy across Native American communities by combining digital banking technology with community-focused outreach and education

- Numerica Credit Union – Helped members save nearly $500,000 in six months through an innovative micro-savings solution that makes saving simple and automatic

The Changemakers

Recognizes financial institutions for outstanding achievements using technology, services, and innovation

- FirstBank – Leveraged Jack Henry's open integration model to create a custom authentication platform that ended contact-center fraud and improved efficiency

- Kitsap Credit Union – Transformed loan quality control through intelligent automation, increasing review coverage to 100% while strengthening operational efficiency and oversight

The Integrators

Recognizes fintechs who are bridging the gap between service and technology delivery, streamlining transaction processing, and helping improve financial outcomes

- Array – Embedded financial wellness capabilities directly into digital banking experiences, helping consumers monitor, manage, and improve their financial health

- Moov – Partnered with Jack Henry to deliver embedded payment solutions that help consumers and small businesses move money faster and manage payments more seamlessly

Each winner is featured in a dedicated case study highlighting its journey, impact, and the technology that helped drive success. Visit jackhenry.com to learn more about the 2026 Cobalt Award winners and their stories.

About Jack Henry & Associates, Inc.®

Jack Henry®(Nasdaq: JKHY) is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. We are an S&P 500 company that prioritizes openness, collaboration, and user centricity – offering banks and credit unions a vibrant ecosystem of internally developed modern capabilities as well as the ability to integrate with leading fintechs. For 50 years, Jack Henry has provided technology solutions to enable clients to innovate faster, strategically differentiate, and successfully compete while serving the evolving needs of their accountholders. We empower more than 7,200 clients with people-inspired innovation, personal service, and insight-driven solutions that help reduce the barriers to financial health. Additional information is available at jackhenry.com.

Statements made in this news release that are not historical facts are "forward-looking statements." Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, those discussed in the Company's Securities and Exchange Commission filings, including the Company's most recent reports on Form 10-K and Form 10-Q, particularly under the heading "Risk Factors." Any forward-looking statement made in this news release speaks only as of the date of the news release, and the Company expressly disclaims any obligation to publicly update or revise any forward-looking statement, whether because of new information, future events or otherwise.

SOURCE Jack Henry & Associates, Inc.

Share this article